Skip to main content
Have a personal or library account? Click to login
Carvedilol and Pycnogenol® improve the function of diabetic hearts in rats Cover

Carvedilol and Pycnogenol® improve the function of diabetic hearts in rats

European Pharmaceutical Journal
Volume 60 (2013): Issue 2 (December 2013)
By: ,  ,  ,   and    
Open Access
|Dec 2013
References

References

  1. [1] Antelava N, Gabunia L, Gambashidze K, Petriashvili Sh, Bejitashvili N: Effect of carvedilol, lozartan and trimetazidin on functional parameters of isolated heart of rats at oxidative stress. Georgian Med News. 2009; 2 (167): 81-84.
    Search in Google Scholar
  2. [2] Battiprolu PK, Gillette TG, Wang ZV, Lavandero S, Hill JA: Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets. Drug Discov Today Dis Mech. 2010; 7 (2): 135-143.
    Open DOISearch in Google Scholar
  3. [3] Bauters C, Lamblin N, Mc Fadden EP, Van Belle E, Millaire A, de Groote P. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovas Diabetol. 2003; 2 (1):1-16.
    Open DOISearch in Google Scholar
  4. [4] Drobna V, Drafi F, Jankyova S: Vplyv polyfenolov na kardiovaskularne poškodenie pri diabetus mellitus. Pokroky vo farmakologii v Slovenskej republike VI, FaF UK 2011; 15-21.
    Search in Google Scholar
  5. [5] El-Sherif N, Turitto G: Electrophysiologic Effects of Carvedilol: Is Carvedilol an Antiarrhythmic Agent? Pace. 2005; 28: 985-990.
    Open DOISearch in Google Scholar
  6. [6] Emre M, Kavak S, Unlugenc H: The effects of telmisartan on mechanical responses of left ventricular papillary muscle in rats with streptozotocin-induced diabetes mellitus. Acta Diabetol. 2010; 47 (1 suppl):153-159.
    Open DOISearch in Google Scholar
  7. [7] Grimm D, Jabusch H, Kossmehl P, Huber M, Fredersdorf S, Griese DP, Kramer BK, Kromer EP: Experimental diabetes and left ventricular hypertrophy. Effects of beta-receptor blockade. Cardiovas Pathology.2002;11: 229-237.
    Open DOISearch in Google Scholar
  8. [8] Goyal BR, Parmar K, Goyal RK, Mehta AA: Beneficial role of telmisartan on cardiovascularcomplications associated with STZ-induced type 2 diabetes in rats. Pharmacol Report. 2011; 63: 956-966.
    Open DOISearch in Google Scholar
  9. [9] Hosseini S, Lee J, Sepulveda RT, Rohdewald P, Watson RR: A randomized, double-blind, placebo-controlled, prospective, 16 week crossover study to determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive patients. Nutr Res. 2001; 21: 1251-1260.
    Open DOISearch in Google Scholar
  10. [10] Huang H, Shan J, Pan X, Wang H, Qian L: Carvedilol protected diabetic rat hearts via reducing oxidative stress. J Zhejiang Univ SCIENCE B. 2006; 7 (9): 725-731.
    Open DOISearch in Google Scholar
  11. [11] Huang H , Shan J, Pan XH , Wang HP , Qian LB, Xia Q: Carvedilol improved diabetic rat cardiac function depending on antioxidant ability. Diabetes Research and Clinical Practice. 2007; 75: 7-13.
    Open DOISearch in Google Scholar
  12. [12] Izraelova, J et.al.:Normalizacia korekcie intervalu QT u potkanov. Zbornik prac, 56. Farmakologicke dni, Bratislava. 2006:149.
    Search in Google Scholar
  13. [13] Jankyova S, Kucera P, Goldenberg Z, Yaghi D, Navarova J, Kyselova Z, Stolc S, Klimas J, Racanska E, Matyas S : Pycnogenol R Efficiency on Glycaemia, Motor Nerve Conduction Velocity and Markers of Oxidative Stress in Mild Type Diabetes in Rats. Phytother. Res. 2009; 23: 1169-1174.
    Search in Google Scholar
  14. [14] Jankyova S, Kmecova J, Cernecka H, Mesarosova L, Musil P, Brnoliakova Z, Kyselovic J, Babal P, Klimas J: Glucose and blood pressure lowering effects of PycnogenolR are inefficient to prevent prolongation of QT interval in experimental diabetic cardiomyopathy. Pathology - Research and Practice. 2012; 208: 452-457.
    Open DOISearch in Google Scholar
  15. [15] Jankyova S, Hlavackova L, Kralova E, Slazneva J, Drobna V, Zuzik P, Drafi F., Mucaji P, Racanska E: The evaluation of efficacy of PycnogenolR fractions on endothelial dysfunction. Acta Fac. Pharm. Univ. Comen., 2013; LX: (1), 7-14.
    Open DOISearch in Google Scholar
  16. [16] Kinsel JF, Straus SE: Complementary and alternative therpaeutics: rigorous research is needed to support claims. In Annual review of pharmacology and toxicology. 2003; 43: 463-484.
    Open DOISearch in Google Scholar
  17. [17] Kitabchi AE, Wall BM: Diabetic ketoacidosis. Med Clin North Am. 1995;79: 9-37.
    Open DOISearch in Google Scholar
  18. [18] Klimas J, Kmecova J, Jankyova S, Yaghi D, Priesolova E., Kyselova Z, Musil P, Ochodnicky P, Krenek P, Kyselovic J, Matyas S: PycnogenolR Improves Left Ventricular Function in Streptozotocin-Induced Diabetic Cardiomyopathy in Rats.Phytother Res. 2010; 24: 969-974.
    Open DOISearch in Google Scholar
  19. [19] Kuželova M: Principy farmakologie kardiovaskularneho systemu pre farmaceutov, vydavateľstvo SAV;Bratislava 2008, 35.
    Search in Google Scholar
  20. [20] Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz R, Howard BV, Welty TK, Lee ET, Devereux RB: The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Car 2001; 37:1943-1949.
    Open DOISearch in Google Scholar
  21. [21] Maimoona A, Naeem I, Saddiqe Z, Jameel K: Review on biological, nutraceutical and clinical aspects of french maritime pine bark. Journal of Ethnopharmacology. 2010; 133(2): 1-53.
    Open DOISearch in Google Scholar
  22. [22] Miller JA, Floras JS, Zinman B, Skorecki KL, Logan AG: Effect of hyperglycemia on arterial pressure, plasma renin activity, and renal function in early diabetes. Clin Sci. 1996; 90:189-195.
    Open DOISearch in Google Scholar
  23. [23] Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334(21):1349-55.
    Open DOISearch in Google Scholar
  24. [24] Packer G, Rimbach F, Virgili R: Antioxidant activity and biologic properties of procyanidin-rich extract from pine (Pinus maritime) bark, Pycnogenol. Free Radical Biol Med.1999; 27: 704-724.
    Open DOISearch in Google Scholar
  25. [25] Ruffolo RR, Bril A, Feuerstein GZ: Cardioprotective potential of carvedilol. Cardiology. 1993;82:24-8.
    Open DOISearch in Google Scholar
  26. [26] Spindler M, Saupe KW, Tian R, Ahmed S, Mohammed A, Ingwall JS: Altered Creatine Kinase Enzyme Kinetics in Diabetic Cardiomyopathy. A 31P NMR Magnetization Transfer Study of the Intact Beating Rat Heart. Mol Cell Cardiol. 1999; 31: 2175-2189.
    Open DOISearch in Google Scholar
  27. [27] Thulesen J, Orskov C, Holst JJ, Poulsen SS: Short Term Insulin Treatment Prevents the Diabetogenic Action of Streptozotocin in Rats. Endocrin. 1997; 138 (1): 62-67.
    Open DOISearch in Google Scholar
  28. [28] Yu X, Tesiram YA, Towner RA, Abbott A, Patterson E, Huang1S, Garrett MW, Chandrasekaran S, Matsuzaki S, Szweda LI, Gordon BE, Kem1 DC. Early myocardial dysfunction in streptozotocin-induced diabetic mice: a study using in vivo magnetic resonance imaging (MRI). Cardiovascular Diabetology. 2007; 6:6 -10.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/afpuc-2013-0019 | Journal eISSN: 2453-6725 (formerly 1338-6786) | Journal ISSN: 0301-2298
Journal RSS Feed
Language: English, Slovak
Page range: 15 - 21
Published on: Dec 31, 2013
Published by: Comenius University in Bratislava, Faculty of Pharmacy
In partnership with: Paradigm Publishing Services
Keywords:
diabetes mellitus - ECG - carvedilol - Pycnogenol® - rat
Related subjects:
Pharmacy,
Pharmacy, other

© 2013 Kráľová E., Jankyová S., Pekárik A., Čuboň J., Stankovičová T., published by Comenius University in Bratislava, Faculty of Pharmacy
This work is licensed under the Creative Commons License.

Volume 60 (2013): Issue 2 (December 2013)
Previous article
Next article